HFS
AKBA icon

HL Financial Services’s Akebia Therapeutics AKBA Stock Holding History

HL Financial Services’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,106
Closed -$56K – 729
2018
Q4 		$56K Buy
+10,106
New +$79.1K ﹤0.01% 710

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

HL Financial Services's AKBA Position: Q1 2019 in Review

HL Financial Services sold out of Akebia Therapeutics (AKBA) in Q1 2019, closing a stake of 10,106 shares — an estimated $56K sold.

HL Financial Services first reported a position in AKBA in Q4 2018 and held it in 1 quarter. The position peaked at $56K in Q4 2018. 169 funds tracked by Wall St. Rank hold AKBA as of Q1 2019.

  • HL Financial Services reported no remaining Akebia Therapeutics position as of Q1 2019 after selling out during the quarter.
  • HL Financial Services sold 10,106 Akebia Therapeutics shares in Q1 2019, an estimated $56K.
  • HL Financial Services first reported a position in Akebia Therapeutics in Q4 2018 and held it in 1 quarter.
  • HL Financial Services's Akebia Therapeutics position peaked at $56K in Q4 2018.
  • 169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2019.

Based on HL Financial Services's 13F filing for Q1 2019, filed 1 May 2019.